| Multiple Sclerosis |
1 |
1 |
| Adverse Effects |
0 |
0.75 |
| Patient Safety |
0 |
0.4 |
| Disease-Modifying Therapy |
0 |
0.38 |
| Cancer |
0 |
0.19 |
| Clinical Research |
0 |
0.19 |
| Disability |
0 |
0.19 |
| Multiple Sclerosis Relapse |
0 |
0.19 |
| Cardiovascular Risk Management |
0 |
0.17 |
| Magnetic Resonance Imaging |
0 |
0.16 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.13 |
| Heart Failure (HF) |
0 |
0.11 |
| Skin Cancer |
0 |
0.11 |
| Basal Cell Carcinoma |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Cardiometabolic Risk Factors |
0 |
0.09 |
| Central Nervous System |
0 |
0.09 |
| Cognition |
0 |
0.09 |
| Colorado |
0 |
0.09 |
| Demyelination |
0 |
0.09 |
| Face |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Heart |
0 |
0.09 |
| Hyperlipidemia |
0 |
0.09 |
| Hypertension |
0 |
0.09 |
| Immunization |
0 |
0.09 |
| Immunosuppressive Therapy |
0 |
0.09 |
| Leukoencephalopathy |
0 |
0.09 |
| Multiple Sclerosis Risk |
0 |
0.09 |
| Neurodegenerative Diseases |
0 |
0.09 |
| Opportunistic Infection |
0 |
0.09 |
| Physiology |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Receptors |
0 |
0.09 |
| Shared Decision-Making |
0 |
0.09 |